876 Non-invasive Monitoring of Metastatic Breast Cancer by Circulating Tumour DNA – a Comparison With Circulating Tumour Cells

2012 ◽  
Vol 48 ◽  
pp. S211-S212
Author(s):  
S. Dawson ◽  
D. Tsui ◽  
M. Murtaza ◽  
H. Biggs ◽  
S.F. Chin ◽  
...  
2021 ◽  
Vol 32 ◽  
pp. S31
Author(s):  
M.A. Papadaki ◽  
C.A. Apostolopoulou ◽  
A. Monastirioti ◽  
D. Aggouraki ◽  
C. Papadaki ◽  
...  

2017 ◽  
Vol 77 (12) ◽  
pp. 1291-1298 ◽  
Author(s):  
Arkadius Polasik ◽  
Marie Tzschaschel ◽  
Fabienne Schochter ◽  
Amelie de Gregorio ◽  
Thomas Friedl ◽  
...  

AbstractDissemination of tumour cells and the development of solid metastases occurs via blood vessels and lymphatics. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) can be detected in venous blood in patients with early and metastatic breast cancer, and their prognostic relevance has been demonstrated on numerous occasions. Repeated testing for CTCs and ctDNA, or regular so-called “liquid biopsy”, can be performed easily at any stage during the course of disease. Additional molecular analysis allows definition of tumour characteristics and heterogeneity that may be associated with treatment resistance. This in turn makes personalised, targeted treatments possible that may achieve both improved overall survival and quality of life.


2012 ◽  
Vol 13 (7) ◽  
pp. 688-695 ◽  
Author(s):  
Anthony Lucci ◽  
Carolyn S Hall ◽  
Ashutosh K Lodhi ◽  
Anirban Bhattacharyya ◽  
Amber E Anderson ◽  
...  

2020 ◽  
Vol 80 (11) ◽  
pp. 1093-1104
Author(s):  
Maggie Banys-Paluchowski ◽  
Natalia Krawczyk ◽  
Tanja Fehm

AbstractIn recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA.


2009 ◽  
Vol 122 (1) ◽  
pp. 211-217 ◽  
Author(s):  
Edoardo Botteri ◽  
Maria Teresa Sandri ◽  
Vincenzo Bagnardi ◽  
Elisabetta Munzone ◽  
Laura Zorzino ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document